Anesthesia Issues in the Perioperative Management of Myasthenia Gravis

 

 Buy Article Permissions and Reprints

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction. Current anesthetic practice may require the use of neuromuscular blocking (NMB) drugs that act at this junction to facilitate control of the airway and allow procedures to be performed on a motionless MG patient. This competes with the goals of rapid emergence and recapture of preoperative muscle strength following anesthesia. In particular, avoiding prolonged periods of postoperative mechanical ventilation is a paramount concern of patients, families, and physicians. Standard anesthetic agents and, if needed, judiciously titrated NMB drugs generally allow safe emergence and immediate extubation for most low-risk MG patients. If necessary, postoperative mechanical ventilation is accomplished with the use of specialized monitoring devices that help monitor awareness and depth of sedation. Currently used intravenous sedatives allow titrated depth of sedation and rapid emergence when extubation is appropriate. Communication to the patient, family, and other caregivers of the goals of the anesthetic plan and of the patient's evolving status are also very important duties of the anesthesiologist.

REFERENCES

• 1 Drachman D B. Myasthenia gravis.  N Engl J Med. 1994;  330 1797-1810
  CrossrefPubMedGoogle Scholar
• 2 Eisenkraft J B, Book W J, Mann S M et al.. Resistance to succinylcholine in myasthenia gravis: a dose-response study.  Anesthesiology. 1988;  69 760-763
  CrossrefPubMedGoogle Scholar
• 3 Mann R, Blobner M, Jelen-Esselborn S et al.. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.  Anesthesiology. 2000;  93 346-350
  PubMedGoogle Scholar
• 4 Leventhal R, Orkin F, Hirsch R. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis.  Anesthesiology. 1980;  53 26-30
  PubMedGoogle Scholar
• 5 Vareles P N, Chua H C, Natterman J. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate.  Crit Care Med. 2002;  30 2663-2668
  PubMedGoogle Scholar
• 6 Lucchi M, Mussi A, Ricciardi R et al.. Thymectomy in ocular myasthenia gravis.  J Thorac Cardiovasc Surg. 2003;  125 740-741
  PubMedGoogle Scholar
• 7 Evoli A, Batocchi A P, Minisci C et al.. Clinical characteristics and prognosis of myasthenia gravis in older people.  J Am Geriatr Soc. 2000;  48 1442-1448
  PubMedGoogle Scholar
• 8 Nakagawa K, Asamura H, Matsuno Y et al.. Thymoma: a clinicopathologic study based on the new World Health Organization classification.  J Thorac Cardiovasc Surg. 2003;  126 1134-1140
  CrossrefPubMedGoogle Scholar
• 9 Poulas K, Tsibri E, Kokla A et al.. Epidemiology of seropositive myasthenia gravis in Greece.  J Neurol Neurosurg Psychiatry. 2001;  71 352-356
  CrossrefPubMedGoogle Scholar
• 10 Chitnis T, Khoury S J. Immunologic neuromuscular disorders.  J Allergy Clin Immunol. 2003;  111 S659-S668
  CrossrefPubMedGoogle Scholar
• 11 Carding P. Voice pathology in the United Kingdom.  BMJ. 2003;  327 514-515
  CrossrefPubMedGoogle Scholar
• 12 Fried M J, Protheroe T. d-Penicillamine induced myasthenia gravis: its relevance for the anesthetist.  Br J Anaesth. 1986;  58 1191-1193
  PubMedGoogle Scholar
• 13 Calhoun R F, Ritter J H, Guthrie T J et al.. Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients.  Ann Surg. 1999;  230 555-561
  CrossrefPubMedGoogle Scholar
• 14 Hart N, Simonds A K. The pulmonary physician in critical care. Illustrative case 4: neuromusculoskeletal disorders.  Thorax. 2003;  58 547-549
  CrossrefPubMedGoogle Scholar
• 15 Wittbrodt E T. Drugs and myasthenia gravis: an update.  Arch Intern Med. 1997;  157 399-408
  CrossrefPubMedGoogle Scholar
• 16 Kokontis L, Gutmann L. Current treatment of neuromuscular diseases.  Arch Neurol. 2000;  57 939-943
  CrossrefPubMedGoogle Scholar
• 17 Kupersmith M J, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.  Arch Neurol. 2003;  60 243-248
  CrossrefPubMedGoogle Scholar
• 18 Miller R G, Milner-Brown H S, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis.  Neurology. 1986;  36 729-732
  PubMedGoogle Scholar
• 19 Ciafaloni E, Nikhar N K, Massey J M et al.. Retrospective analysis of the use of cyclosporine in myasthenia gravis.  Neurology. 2000;  55 448-450
  CrossrefPubMedGoogle Scholar
• 20 Meriggioli M N, Ciafaloni E, Al-Hayk K A et al.. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.  Neurology. 2003;  61 1438-1440
  CrossrefPubMedGoogle Scholar
• 21 Bathon J M, Martin J W, Fleishman R M et al.. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.  N Engl J Med. 2000;  343 1586-1593
  CrossrefPubMedGoogle Scholar
• 22 Dalakas M C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies.  Neurology. 2002;  59 S13-S21
  CrossrefPubMedGoogle Scholar
• 23 Wylam M E, Anderson P M, Kuntz N L et al.. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.  J Pediatr. 2003;  143 674-677
  CrossrefPubMedGoogle Scholar
• 24 Newsom-Davis J, Vincent A, Wilson S G et al.. Long term effects of repeated plasma exchange in myasthenia gravis.  Lancet. 1979;  1 464-468
  PubMedGoogle Scholar
• 25 Gronset G, Barohn R. Practice parameter: thymectomy for autoimmune myasthenia gravis.  Neurology. 2000;  55 7-15
  CrossrefPubMedGoogle Scholar
• 26 Ruff R L, Batchelor T T, Taylor L P et al.. Steroid myopathy in cancer patients.  Neurology. 1997;  48 1234-1238
  PubMedGoogle Scholar
• 27 Ruff R L. Acute illness myopathy.  Neurology. 1996;  46 600-601
  PubMedGoogle Scholar
• 28 Gutmann L, Blumenthal D, Schochet S S. Acute type II myofiber atrophy in critical illness.  Neurology. 1996;  46 819-821
  PubMedGoogle Scholar
• 29 Rich M M, Teener J W, Raps E C et al.. Muscle is electrically inexcitable in acute quadriplegic myopathy.  Neurology. 1996;  46 731-736
  CrossrefPubMedGoogle Scholar
• 30 Eisenkraft J B, Papatestas A E, Kahn C H et al.. Predicting the need for postoperative mechanical ventilation in myasthenia gravis.  Anesthesiology. 1986;  65 79-82
  PubMedGoogle Scholar
• 31 Erlacher W, Kontaratos M, Muller C et al.. Intubation without muscle relaxation: alfentanil/propofol as an alternative induction regime for children.  Anesthesiology. 1998;  89(suppl) 1316A
  PubMedGoogle Scholar
• 32 Bell C F, Florence A M, Hunter J M et al.. Atracurium in the myasthenic patient.  Anaesthesia. 1984;  39 961-968
  PubMedGoogle Scholar
• 33 Hunter J M, Bell C F, Florence A M et al.. Vecuronium in the myasthenic patient.  Anaesthesia. 1985;  40 848-853
  PubMedGoogle Scholar
• 34 Rowlee S. Monitoring neuromuscular blockade in the intensive care unit: the peripheral nerve stimulator.  Heart Lung. 1999;  28 352-362
  CrossrefPubMedGoogle Scholar
• 35 Goldman L, Caldera D L, Nussbaum S R et al.. Multifactorial index of cardiac risk in non-cardiac surgical procedures.  N Engl J Med. 1977;  297 845-850
  CrossrefPubMedGoogle Scholar
• 36 Ely E W, Baker A M, Dunagan D P et al.. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously.  N Engl J Med. 1996;  335 1864-1869
  CrossrefPubMedGoogle Scholar
• 37 Esteban A, Frutos F, Tobin M J et al.. A comparison of four methods of weaning patients from mechanical ventilation.  N Engl J Med. 1995;  332 345-350
  CrossrefPubMedGoogle Scholar
• 38 Adrogué H J, Madias N E. Management of life-threatening acid-base disorders, I and II.  N Engl J Med. 1998;  338 26-34 107-111
  CrossrefPubMedGoogle Scholar
• 39 Yende S, Wunderink R. Causes of prolonged mechanical ventilation after coronary artery bypass surgery.  Chest. 2002;  122 245-252
  CrossrefPubMedGoogle Scholar
• 40 Adnet F, Baud F. Relation between Glasgow Coma Scale and aspiration pneumonia.  Lancet. 1996;  348 123-124
  PubMedGoogle Scholar
• 41 Kim K, Lew S, Cho H Y et al.. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine.  Anesth Analg. 2002;  95 1656-1660
  PubMedGoogle Scholar
• 42 Gennari F J. Hypokalemia.  N Engl J Med. 1998;  339 451-458
  CrossrefPubMedGoogle Scholar
• 43 Subramanian R, Khardori R M. Severe hypophosphatemia: pathophysiologic implications, clinical presentations, and treatment.  Medicine (Baltimore). 2000;  79 1-8
  CrossrefPubMedGoogle Scholar
• 44 Oelkers W. Adrenal insufficiency.  N Engl J Med. 1996;  335 1206-1212
  CrossrefPubMedGoogle Scholar
• 45 Nair S R, Pearson S B. Mucous plug in the bronchus causing lung collapse.  N Engl J Med. 2002;  347 1079
  CrossrefPubMedGoogle Scholar
• 46 Fawcett W J, Stone J P. Recurarization in the recovery room following the use of magnesium sulphate.  Br J Anaesth. 2003;  91 435-438
  CrossrefPubMedGoogle Scholar
• 47 McDonald C M. Physical activity, health impairments, and disability in neuromuscular disease.  Am J Phys Med Rehabil. 2002;  81 S108-S120
  CrossrefPubMedGoogle Scholar
• 48 Ashworth S F, Cordingly J J. New modes of ventilation.  Curr Anesth Crit Care. 2003;  14 90-99
  PubMedGoogle Scholar
• 49 Vivien B, Di Maria S, Ouattara A et al.. Overestimation of bispectral index in sedated intensive care unit patients revealed by administration of muscle relaxant.  Anesthesiology. 2003;  99 9-17
  CrossrefPubMedGoogle Scholar
• 50 Messner M, Beese U, Romstöck J K. The bispectral index declines during neuromuscular block in fully awake persons.  Anesth Analg. 2003;  97 488-491
  PubMedGoogle Scholar
• 51 Antonelli M, Conti G, Rocco M et al.. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure.  N Engl J Med. 1998;  339 429-435
  CrossrefPubMedGoogle Scholar
• 52 Hart N, Simonds A K. The pulmonary physician in critical care. Illustrative case 4: neuromusculoskeletal disorders.  Thorax. 2003;  58 547-549
  CrossrefPubMedGoogle Scholar
• 53 Rabinstein A, Wijdicks E FM. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation.  Neurology. 2002;  59 1647-1649
  CrossrefPubMedGoogle Scholar
• 54 Djelmis J, Sostarko M, Mayer D et al.. Myasthenia gravis in pregnancy: report on 69 cases.  Eur J Obstet Gynecol Reprod Biol. 2002;  104 21-25
  CrossrefPubMedGoogle Scholar
• 55 Hoff J M, Daltveit A K, Gilhus N E. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn.  Neurology. 2003;  61 1362-1366
  CrossrefPubMedGoogle Scholar

Francis X DillonM.D. 

Department of Anesthesia, Indiana University School of Medicine

Fesler Hall, Room 204, 1120 South Drive

Indianapolis, IN 46202-5115